Artificial Intelligence in Genomics Market
Report ID: SQMIG35G2496
Report ID: SQMIG35G2496
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35G2496 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
119
|Figures:
77
Global Artificial Intelligence In Genomics Market size was valued at USD 1.09 Billion in 2024 and is poised to grow from USD 1.51 Billion in 2025 to USD 20.31 Billion by 2033, growing at a CAGR of 38.4% during the forecast period (2026-2033).
The primary driver of the artificial intelligence in genomics market is the exponential increase in genomic data generation coupled with the need for actionable interpretation, which has transformed sequencing from an isolated research tool into a clinical platform with scalability. This market encompasses software, algorithms and services that convert sequence reads into clinically relevant insights for diagnosis, drug discovery and population health. It matters because faster, more accurate variant calling and phenotype prediction reduce time-to-treatment and lower costs, exemplified by AI-assisted rare disease diagnosis shortening diagnostic odysseys and oncology firms applying deep learning to stratify tumor subtypes for targeted therapies.
Building on surge in sequencing throughput, a key factor in Global Artificial Intelligence in Genomics Market Market is integration of multi-omics datasets with clinical records, because such synthesis enables models to detect subtle disease signatures and predict treatment response more reliably. As a result, companies fuse genomics, transcriptomics and EHR data to accelerate biomarker discovery, which shortens clinical trial timelines and attracts biopharma partnerships exemplified by collaborations that yielded AI-nominated neoantigens for cancer vaccines and pharmacogenomic algorithms informing dosing. This causal chain creates opportunities in companion diagnostics, population screening and drug repurposing while cloud infrastructure and regulatory acceptance expand adoption.
How is AI transforming the genomics market's diagnostic and drug discovery capabilities?
AI is reshaping genomics by improving diagnostic clarity and speeding drug discovery. Key aspects include integration of large scale molecular and clinical data, machine learning for variant interpretation, and AI powered models that link multiomics and spatial biology to patient outcomes. The market is moving beyond experiments into commercial pipelines as platform companies and model builders partner to convert complex molecular readouts into actionable biomarkers and prioritized targets.
Examples span foundation models for biological sequence and spatial platforms that produce the high fidelity data needed to train predictive systems. The outcome is faster hypothesis testing and more confident preclinical decision making. Basecamp Research March 2026, launched the Trillion Gene Atlas to generate massive, diverse genomic datasets for AI model training. This innovation feeds richer training data into AI systems, improving target identification and making discovery workflows more efficient which supports market growth and faster translation of genomic insights into diagnostics and therapies.
Market snapshot - (2026-2033)
Global Market Size
USD 1.09 Billion
Largest Segment
Software
Fastest Growth
Software
Growth Rate
38.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global artificial intelligence in genomics market is segmented by component, functionality, application, technology and region. Based on component, the market is segmented into Hardware, Software, Services and Others. Based on functionality, the market is segmented into Genome Sequencing, Gene Editing and Others. Based on application, the market is segmented into Drug Discovery and Development, Precision Medicine, Diagnostics and Others. Based on technology, the market is segmented into Machine Learning, Computer Vision and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Software segment dominates because it provides the orchestration layer that turns raw genomic data into actionable insights by integrating analytics, data management and visualization into unified platforms. Centralized software enables reproducible pipelines, interoperability with sequencing instruments and rapid deployment of new algorithms, which lowers adoption barriers, attracts partnerships across labs and industry, and fosters ecosystems that continuously improve platform capabilities and sustain market leadership.
However, Services is emerging as the most rapidly expanding area, driven by demand for implementation, custom model training and managed operations that translate prototype AI into validated laboratory workflows. Service providers bridge gaps in domain expertise, regulatory navigation and infrastructure, accelerating uptake among organizations that lack in house capabilities and creating recurring revenue models that broaden market opportunity.
Machine learning segment dominates because its algorithms enable predictive interpretation of complex genomic signals, transforming variant calling, phenotype association and biomarker discovery through model driven pattern recognition. Continuous advances in architectures, training strategies and curated datasets improve accuracy and generalizability, which drives integration across research and clinical pipelines and attracts sustained investment into tooling and validation efforts that reinforce leadership.
Meanwhile, computer vision is witnessing the strongest growth momentum as digitized imaging and spatial omics create demand for automated feature extraction and phenotype mapping in histology and microscopy. Advances in image analysis tools and adoption in diagnostics and translational research are unlocking new applications that expand the addressable market for AI in genomics.
To get detailed segments analysis, Request a Free Sample Report
North America dominates due to a confluence of strengths that include expansive research infrastructure, leadership in computational technologies, and robust commercialization mechanisms that translate discovery into marketable solutions. Premier academic institutions, specialized genomics centers, and large technology companies collaborate closely with a dynamic biotech industry, generating sustained innovation in AI driven genomics. Integrated healthcare systems and translational networks provide access to heterogeneous clinical datasets that support model training and validation. Active capital markets and experienced entrepreneurial networks enable rapid scaling, while regulatory frameworks and reimbursement pathways that accommodate clinical validation promote adoption. Cross sector partnerships, talent concentration across data science and molecular biology, and an established culture of public private collaboration collectively create an environment where AI enabled genomics products advance from concept to clinical use more readily than in other regions.
Artificial Intelligence in Genomics Market in the United States is characterized by deep integration of advanced computational platforms with clinical research infrastructure, strong collaboration between technology firms and academic institutions, and concentration of specialized talent and capital. Adoption focuses on translational research, precision medicine initiatives, and private sector innovation pipelines, supported by comprehensive data ecosystems and established commercialization pathways that accelerate development and deployment of genomics driven solutions at scale.
Artificial Intelligence in Genomics Market in Canada reflects a collaborative research ecosystem that blends publicly funded research networks with biotech initiatives, enabling targeted algorithm development and localized genomic datasets. Emphasis rests on partnerships between hospitals, research institutes, and industry to tailor AI models for population specific applications, while policy frameworks and cross provincial data initiatives encourage secure data sharing, ethical oversight, and clinical translation of genomic AI tools into practice.
Europe is experiencing rapid expansion driven by concentrated research excellence across multiple national centers, progressive regulatory frameworks that emphasize safe data use, and a collaborative culture that encourages public private partnerships. Robust clinical networks and pan European initiatives facilitate cross border data sharing and multicenter validation of AI models, while strong pharmaceutical and biotech presence accelerates translation into therapeutic development and diagnostics. Growing investment in bioinformatics talent, supportive innovation ecosystems, and targeted policy measures cultivate commercialization pathways. Differentiated national strengths result in variable adoption patterns, with some countries advancing quickly through industrial collaboration and others focusing on ethical governance and clinical integration, collectively elevating the role of Europe in global genomics AI innovation.
Artificial Intelligence in Genomics Market in Germany is propelled by a strong engineering tradition and focused investment in computational biology, fostering adoption of machine learning across genomics research and industrial applications. Collaborative networks between research centers, technology vendors, and biotech firms drive commercialization, while emphasis on translational pipelines and targeted workforce development supports integration of AI driven genomics into diagnostics, personalized therapy research, and national bioinformatics service offerings and infrastructure.
Artificial Intelligence in Genomics Market in the United Kingdom demonstrates leadership through an ecosystem of academic medical centers, biotech firms, and national health research initiatives that accelerate clinical translation. Regulatory engagement and established clinical infrastructure combined with active industry collaboration support development of clinically oriented AI genomics solutions. Focus on interoperability, data governance, and public private partnerships enables movement from discovery to diagnostic and therapeutic tools integrated within care pathways.
Artificial Intelligence in Genomics Market in France is emerging with emphasis on translational research hubs, national institutes, and startup communities that adapt AI methods to healthcare priorities. Academic industry collaborations and supportive research programs encourage development of localized genomic datasets and ethical frameworks. Attention to regulatory convergence, skills development, and tailored clinical validation pathways positions the market for integration of AI driven genomics into patient centered care models and services.
Asia Pacific is strengthening its position through coordinated investments in computational infrastructure, strategic industry academic partnerships, and focused national initiatives that prioritize precision medicine and genomic research. Regional technology leaders contribute advanced semiconductor and cloud computing capabilities that support large scale data processing and sophisticated AI modeling. Rapid maturation of local biotech ecosystems, growing expertise in bioinformatics, and proactive regulatory modernization foster clinical validation and commercialization pathways. Cross border collaborations and global partnerships enable knowledge transfer and access to broader markets, while emphasis on workforce development and translational research hubs cultivates locally relevant solutions. Collectively, these elements are enhancing the capacity of the region to develop and deploy AI driven genomics applications with greater scale and local relevance. Investment in translational infrastructure and partnerships with global clinical networks further supports validation and adoption across diverse healthcare settings.
Artificial Intelligence in Genomics Market in Japan benefits from advanced IT infrastructure, strong industrial research, and collaboration between universities, medical centers, and technology corporations. National emphasis on precision medicine and age related healthcare drives development of genomic AI solutions aligned with clinical needs. Semiconductor and hardware expertise supports efficient data processing, while growing startup activity and focused pilot programs validate algorithms in medical settings and establish pathways toward clinical adoption.
Artificial Intelligence in Genomics Market in South Korea is supported by technology infrastructure, biotech investment, and close collaboration between research hospitals and technology firms. Emphasis on computing and analytics enables development of AI models for genomic interpretation. Innovation programs and incubators nurture startups, while partnerships with domestic pharmaceutical companies and international research centers aid clinical validation and market entry of AI enabled genomics solutions broadly aligned with regional healthcare priorities.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Computational Methods
Growing Integration With Clinical Practice
Regulatory Uncertainty and Data Governance
Limited Availability Of Curated Data
Request Free Customization of this report to help us to meet your business objectives.
Competition in the artificial intelligence genomics market is driven by pharma partnerships, selective acquisitions, and platform differentiation through novel machine learning models. Large platform firms secure long term collaborations with drug companies to access clinical datasets while startups pursue specialized AI stacks. Recent market activity shows insitro partnering with major pharma, WhiteLab Genomics striking deals with Debiopharm, and selective acquisitions consolidating analytics platforms.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global artificial intelligence in genomics market is poised for rapid expansion. One key driver is the exponential increase in genomic data generation coupled with demand for actionable interpretation, and a second driver is integration of multi-omics datasets with clinical records that enhances predictive power. One restraint is regulatory uncertainty and evolving data governance which slows adoption and complicates cross border data use. Dominating region is North America due to its research infrastructure, capital and clinical networks, while dominating segment is software because it orchestrates data pipelines, analytics and deployment. Overall the market shows strong clinical and commercial momentum despite governance challenges.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.09 Billion |
| Market size value in 2033 | USD 20.31 Billion |
| Growth Rate | 38.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Artificial Intelligence in Genomics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Artificial Intelligence in Genomics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Artificial Intelligence in Genomics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Artificial Intelligence in Genomics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Artificial Intelligence In Genomics Market size was valued at USD 1.09 Billion in 2024 and is poised to grow from USD 1.51 Billion in 2025 to USD 20.31 Billion by 2033, growing at a CAGR of 38.4% during the forecast period (2026-2033).
Competition in the artificial intelligence genomics market is driven by pharma partnerships, selective acquisitions, and platform differentiation through novel machine learning models. Large platform firms secure long term collaborations with drug companies to access clinical datasets while startups pursue specialized AI stacks. Recent market activity shows insitro partnering with major pharma, WhiteLab Genomics striking deals with Debiopharm, and selective acquisitions consolidating analytics platforms. 'IBM', 'Microsoft', 'Nvidia', 'Deep Genomics', 'BenevolentAI', 'Fabric Genomics', 'Verge Genomics', 'Freenome Holdings', 'MolecularMatch', 'SOPHiA GENETICS', 'Data4Cure', 'PrecisionLife', 'Illumina', 'Qiagen', 'Thermo Fisher Scientific', 'Tempus', 'Freenome', 'Engine Biosciences', 'Sophia Genetics', 'Congenica'
AI driven algorithms enable deeper interpretation of genomic sequences, accelerating discovery of biological patterns and biomarkers and improving predictive models. By enhancing pattern recognition and variant interpretation, these computational advances reduce time to insight and make complex data actionable for researchers and clinicians. The resulting better signal extraction from raw data expands the utility of genomics across disease research and personalized medicine, encouraging investment and adoption of integrated AI solutions that streamline workflows and facilitate collaboration between computational scientists and life science stakeholders.
Clinical Translation Acceleration: AI-driven analytics are enabling faster translation of genomic discoveries into clinical applications by improving variant interpretation, biomarker identification and patient stratification. Enhanced model interpretability and integration with electronic health workflows increase clinician confidence and institutional adoption. Strategic collaborations among technology vendors, biopharma and clinical laboratories streamline validation and regulatory pathways, while service models shift toward end-to-end offerings that bundle analytics, interpretation and reporting. This trend accelerates time-to-clinic for diagnostics and targeted therapies, creating value propositions around clinical utility and scalability.
Why does North America Dominate the Global Artificial Intelligence in Genomics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
